The global demand for highly potent drugs is growing rapidly, with the market projected to reach $46.9B by 2030, driven by innovations in drug delivery technologies, regulatory advancements, and the rising need for personalized treatments. The oncology sector has been a key witness to this, experiencing substantial growth due to the increasing adoption of small molecules, conjugates, and other targeted therapies. 

At the forefront of it all, we’re thrilled to announce that the 14th Highly Potent Drug Manufacturing Summit is back in August 2025, offering in-depth case studies on the latest innovations in developing cytotoxic compounds, strengthening process collaborations, and safely scaling up manufacturing. 

As a free-to-attend* event for drug developers this year in Boston, you’ll experience a completely revamped agenda, designed to meet the industry’s evolving needs of 90+ Vice Presidents, Directors, and Heads of CMC, Tech Operations, Process Chemistry, Drug Substance and Product, EHS, and Industrial Hygiene. 

Whether you’d like to secure the best CDMO, optimize upstream development, or create a work environment conducive to occupational safety, this is the place to be! 

Hear from some of our most renowned speakers and network with your forward-thinking peers from the likes of Pfizer, Bristol Myers Squibb, Johnson & Johnson, Biogen, Teva Pharmaceuticals, Relay Therapeutics, and more.